{
    "2019-12-29": [
        [
            {
                "time": "",
                "original_text": "贝达药业(300558.SZ)收到CDE签发的关于盐酸恩沙替尼原料药和制剂的补充资料通知书",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "CDE",
                        "盐酸恩沙替尼",
                        "原料药",
                        "制剂",
                        "补充资料通知书"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【国盛医药张金洋团队】周观点：肝素到底是不是周期还是成长？——兼论全球肝素产业链重构",
                "features": {
                    "keywords": [
                        "国盛医药",
                        "张金洋",
                        "肝素",
                        "周期",
                        "成长",
                        "产业链重构"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}